Core Viewpoint - VolitionRx Limited has announced a public offering of 11,550,000 shares of common stock and warrants, aiming to raise approximately $6.0 million in gross proceeds before expenses [1][3]. Offering Details - The public offering price is set at $0.52 per share, with each warrant priced at $0.01, and an exercise price of $0.60 per share [1]. - The underwriter has a 30-day option to purchase an additional 1,732,500 shares and warrants to cover overallotments [2]. - If the warrants are fully exercised, the additional gross proceeds could reach approximately $6.9 million [3]. Use of Proceeds - The net proceeds from the offering will be utilized for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [4]. Company Overview - Volition is a multinational company focused on advancing epigenetics, aiming to improve early detection and monitoring of diseases [8]. - The company is developing cost-effective blood tests for various diseases, including certain cancers and conditions associated with NETosis [9]. - Research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [10].

Company Performance - Apogee Enterprises Inc. reported better-than-expected second-quarter financial results, with shares gaining 1.4% to $42.00 in after-hours trading [2] - Levi Strauss & Co. reported third-quarter earnings of 34 cents per share, exceeding the analyst consensus estimate of 31 cents per share, and quarterly sales of $1.543 billion, surpassing the estimate of $1.501 billion; however, shares fell 7.7% to $22.65 in after-hours trading [2] - VolitionRX Ltd. announced a public offering of common stock and common stock warrants, leading to a 20% dip in shares to $0.48 in after-hours trading [2] - USANA Health Sciences Inc. reported preliminary third-quarter results with an adjusted loss of 15 cents per share and sales of $214.00 million, resulting in an 11.4% decline in shares to $23.26 in after-hours trading [2] - Nurix Therapeutics Inc. reported worse-than-expected third-quarter financial results, causing shares to fall 5.7% to $10.24 in after-hours trading [2]

Core Viewpoint - VolitionRx Limited is proposing an underwritten public offering of its common stock and accompanying purchase warrants, with a potential additional 15% option for the underwriter [1][2]. Group 1: Offering Details - The offering will be made under a "shelf" registration statement previously filed with the SEC, and the final terms will depend on market conditions [3]. - Newbridge Securities Corporation is acting as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [2]. Group 3: Company Overview - Volition is a multinational company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancers and conditions associated with NETosis [5][6]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [7].

Company Overview - Volition is a multinational company with laboratories in Belgium and San Diego, USA, focused on stabilizing and improving health outcomes for millions globally [4]. Technology Insights - The presentation highlights the Nu.Q technology, which is aimed at accelerating epigenetic drug development [3][4]. - Nucleosomes, the fundamental structural units of chromatin, are essential for compacting DNA into chromosomes, allowing the genome to fit into the cell nucleus [5].

Summary of the Webinar on Epigenetic Modifications for Biomarker and Drug Discovery Industry and Company Involved - **Industry**: Biotechnology focusing on epigenetic modifications and cancer diagnostics - **Companies**: Volition and HelioGenomics Core Points and Arguments 1. **Overview of Volition**: Volition is a multinational company with R&D labs in Belgium and the U.S., aiming to save lives through innovative diagnostic technologies [2][3] 2. **Nucleosomes and Epigenetic Modifications**: Nucleosomes, composed of DNA and histone proteins, undergo various post-translational modifications (PTMs) that regulate gene expression and are implicated in diseases like cancer [3][4] 3. **Nuclear Assays**: Volition's nuclear assays quantitatively measure circulating nucleosomes and their modifications, with a portfolio of 14 assays targeting specific epigenetic features [4][5] 4. **Diagnostic Potential**: H3K27 trimethylation levels were significantly elevated in non-small cell lung cancer (NSCLC) patients, showing a 3.7 to 2.9-fold increase compared to healthy controls, indicating its potential as a diagnostic biomarker [11][12] 5. **Prognostic Value**: Elevated levels of H3K27 trimethyl nucleosomes were associated with worse outcomes in NSCLC, with a hazard ratio of 3.56, suggesting its use as a prognostic biomarker [41] 6. **Combination with ctDNA**: Combining H3K27 trimethyl status with circulating tumor DNA (ctDNA) improved patient identification by 15.1%, enhancing the sensitivity of blood-based assays [13][50] 7. **EZH2 Inhibitors**: EZH2 inhibitors, such as ORIC-944, show promise in treating cancers by targeting the PRC2 complex, with ongoing clinical trials demonstrating their efficacy [16][17] 8. **Immunogenicity Enhancement**: EZH2 inhibition can increase tumor visibility to the immune system, enhancing the efficacy of immunotherapies by promoting T cell infiltration and activation [27][55] 9. **Clinical Trials**: Multiple clinical trials are investigating the combination of EZH2 inhibitors with immune checkpoint blockade therapies, indicating a strategic shift towards immunoepigenetic combinations [30][57] Other Important but Possibly Overlooked Content 1. **Assay Development Support**: Volition offers support for customizing assays tailored to specific drug programs and matrices, indicating a collaborative approach with pharmaceutical partners [54] 2. **Toxicity Detection**: The H3.1 nuclear assay can serve as an early indicator of systemic cell death, providing a sensitive method for detecting toxicity during drug development [42] 3. **Logistical Considerations**: Proper sample collection and processing are crucial for assay accuracy, with specific recommendations for handling plasma samples [48][58] 4. **Specificity of Assays**: The assays are designed to specifically detect intact circulating nucleosomes without cross-reactivity to other histone modifications [46][53] This summary encapsulates the key insights from the webinar, highlighting the advancements in epigenetic assays and their implications for cancer diagnostics and treatment.

Core Insights - VolitionRx Limited is sponsoring a GenomeWeb webinar focused on epigenetic modifications for biomarker and drug discovery, scheduled for October 8, 2025 [1][2]. Company Overview - VolitionRx is a multi-national epigenetics company dedicated to advancing the science of epigenetics, aiming to improve outcomes for patients with life-altering diseases through early detection and monitoring [7][8]. - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including certain cancers and conditions associated with NETosis, such as sepsis [8]. Webinar Details - The webinar will feature Dr. Eric Ariazi discussing major epigenetic pathways and their implications in health and disease, particularly focusing on cancer immunoediting and pharmacologic inhibitors [3]. - Dr. Marielle Herzog will present case studies on Volition's Nu.Q assays, which are designed to support disease research and clinical development [4]. Nu.Q® Discover Program - The Nu.Q® Discover program offers drug developers and scientists access to advanced assays for rapid epigenetic profiling, facilitating research from discovery to market readiness [5][6]. - This program utilizes proprietary nucleosome quantification technology, serving as a valuable tool for R&D professionals in pharmaco-epigenetics [6].

Core Insights - VolitionRx Limited has signed a co-marketing agreement with Hologic Diagenode to promote its Nu.Q Discover service, which focuses on epigenetic profiling for drug developers and scientists [1][3][4] Company Overview - VolitionRx is a multi-national epigenetics company dedicated to advancing the science of epigenetics, aiming to improve outcomes for patients through earlier detection and monitoring of diseases [12][13] - Hologic, a company with over $4 billion in revenue for 2024, specializes in medical technologies and has extensive experience in various disease areas, including oncology and immunology [5][10] Product and Market Potential - The Nu.Q Discover service offers state-of-the-art assays for rapid epigenetic profiling, with an estimated total addressable market of $200 million annually [4][7] - The partnership aims to expand customer access to Nu.Q Discover assays, potentially leading to Hologic becoming an exclusive provider of these services [3][4] Strategic Goals - The collaboration is expected to enhance the reach of Nu.Q Discover services, leveraging Hologic's established client base and international presence [5][6] - Both companies aim to create value for clients by identifying specific epigenetic signatures that can inform personalized medicine approaches [6]

Core Viewpoint - Biotech stocks are experiencing renewed momentum, with small-cap companies like Nautilus Biotechnology, PepGen, Lixte, RenovoRx, Genelux, and VolitionRx attracting investor interest through various catalysts such as insider buying, strategic partnerships, and clinical trial progress Group 1: Nautilus Biotechnology (NAUT) - Nautilus Biotechnology's stock surged 5.52% during regular trading, closing at $0.7070, and rose an additional 7.5% in after-hours trading to $0.76, with trading volume nearly double its average at 647,399 shares [2] - Recent insider buying by CEO Sujal M. Patel, who purchased 83,500 shares on September 8 and 116,500 shares on September 5, totaling over $135,000, indicates strong leadership confidence [3] - The company reported a narrower loss of $0.12 per share in Q2 2025, with an 18% drop in operating expenses, and has $179.5 million in cash, providing a financial runway through 2027 [4] Group 2: PepGen Inc. (PEPG) - PepGen's stock rebounded 7.14% in after-hours trading to $1.50 after a regular session close of $1.40, with trading volume more than double its average at 638,576 shares [4] - The company completed dosing for its 15 mg/kg arm of the FREEDOM trial, with topline data expected in early Q4 2025, following a strategic narrowing of its pipeline [5] Group 3: Lixte Biotechnology Holdings Inc. (LIXT) - Lixte's stock rose 5.85% in after-hours trading to $5.25 after closing at $4.96, with a trading volume of 503,604 shares, notable given recent volatility [5] - The company announced a $2.6 million purchase of Bitcoin and Ethereum to diversify its treasury holdings, reflecting a strategic shift in financial strategy [6] Group 4: RenovoRx Inc. (RNXT) - RenovoRx shares increased 4.22% in after-hours trading to $1.2194 after a regular session close of $1.17, with trading volume significantly above its average at 886,119 shares [6] - The company received a positive recommendation to continue its Phase III TIGeR-PaC trial for pancreatic cancer, reinforcing confidence in its lead therapy platform [7] Group 5: Genelux Corp. (GNLX) - Genelux's stock rose 4.11% in after-hours trading to $3.80 after closing at $3.65, with trading volume relatively light at 60,339 shares [8] - The recent activity follows Genelux's participation in the H.C. Wainwright Global Investment Conference [9] Group 6: VolitionRx Ltd. (VNRX) - VolitionRx's stock increased 4.27% in after-hours trading to $0.6474 after closing at $0.6209, with trading volume slightly below its average at 183,777 shares [10] - The company announced a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center, focusing on advancing its Nu.Q NETs assay for Antiphospholipid Syndrome [10]

Core Insights - VolitionRx Limited has signed a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome (APS) with Werfen's Immunoassay Technology Center, a leader in specialized diagnostics [1][2][3] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics and developing cost-effective blood tests for early detection and monitoring of diseases [13][14] - Werfen is a family-owned company founded in 1966, specializing in diagnostics in areas such as Hemostasis and Autoimmunity, with worldwide sales of €2.2 billion in 2024 [12] Agreement Details - The agreement allows Werfen to access Volition's proprietary Nu.Q® H3.1 NETs assay to investigate its clinical utility in managing APS patients [3][4] - Werfen has the option to negotiate exclusive commercial rights for launching the product [3] Clinical Implications - APS affects approximately four million people globally and is associated with increased risks of blood clots and complications such as stroke and heart attack [5][10] - The Nu.Q® NETs test is being investigated as a potential biomarker for APS, which could improve diagnostic information and patient monitoring [7][8] Technological Advancements - Early results from the Nu.Q® NETs assay on Werfen's ACL AcuStar® platform show promising detection levels in APS patients [4] - The collaboration aims to validate the clinical utility of the Nu.Q® test as a risk indicator for thrombosis in APS patients [4][6]

Financial Data and Key Metrics Changes - Total operating expenses for Q2 2025 declined by 9% compared to 2024, primarily due to lower personnel and research and development costs [6] - Net cash used in operating activities was $6,300,000 for Q2 2025, down from $6,700,000 in 2024, with total cash used in operations for the first half of 2025 totaling $10,600,000, a 30% decrease year-over-year [6][7] - Revenue for Q2 2025 was over $400,000, bringing total revenue for the first half of 2025 to a little over $650,000, representing a 15% increase compared to the same period in 2024 [6][7] Business Line Data and Key Metrics Changes - The company recorded its first revenue from sales of a human product, Nu. Q Net, marking a significant milestone in its commercialization efforts [6] - The Nu. Q Cancer and Nu. Q Nets pillars have shown significant progress, with independent studies confirming the effectiveness of their biomarkers [9][14] - The Nu. Q Vet cancer test continues to expand globally, with supply agreements in place with leading industry players [34][35] Market Data and Key Metrics Changes - The total addressable market for cancer and sepsis diagnostics is estimated at approximately $25 billion annually, presenting substantial revenue opportunities for the company and its partners [21] - The potential market for the Nu. Q test in lung cancer screening could exceed $1 billion annually across Taiwan, the U.S., U.K., and France [24] Company Strategy and Development Direction - The company aims to achieve cash neutrality for the full year 2025 by executing licensing agreements with significant upfront payments and reducing expenditures [5] - The focus for 2025 is on commercializing the Nu. Q platform in the human diagnostic market, with ongoing discussions with over 10 companies [19][20] - The strategy includes leveraging existing CE Marked products for NETosis-related diseases while expanding into new markets through licensing agreements [26][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in licensing discussions and the potential for significant revenue generation from upcoming deals [19][20] - The company is confident in the robustness and reliability of its platform, which has applications across various clinical areas, including cancer and sepsis [92] - Management anticipates that the next few quarters will be pivotal for securing licensing agreements and advancing commercialization efforts [42][92] Other Important Information - The company has made substantial progress in its clinical study programs, with ongoing collaborations and studies expected to yield further validation of its products [9][12] - The company is exploring co-marketing partnerships to enhance the reach of its Nu. Q Discover platform [41] Q&A Session Summary Question: Which uses of the Nu. Q platform have attracted the most attention from potential partners in the human health space? - Management indicated that interest spans across all areas, including Discover, NETosis, and oncology, with significant engagement from major diagnostic and pharmaceutical companies [46][49] Question: How will the company utilize capital from executed deals to drive revenues? - The company plans to use capital to achieve revenue neutrality and expects varying deal structures across different applications, with some anticipated to yield large payments and ongoing revenues [55][56] Question: Can details be provided on the first human deal's indication or application? - While specifics were not disclosed due to confidentiality, management emphasized that all deals will leverage the robust and reliable Nu. Q test [63][65] Question: What is the expected timeline from licensing a deal to commercialization? - The timeline varies, with immediate revenue possible for some deals, while others may take two to three years for regulatory approval [70][73] Question: Are there any regulatory bodies that need to approve the Taiwan screening program before full production? - Management confirmed that the current validation study is ongoing, and if successful, the test could be launched quickly in a clear lab setting [77][80]